Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
INSMED (NASDAQ: INSM) Delayed: 98.61 +2.81 (2.93%)
Previous Close $95.80    52 Week High $19.30 
Open $95.82    52 Week Low $9.02 
Day High $99.88    P/E N/A 
Day Low $95.27    EPS $-1.69 
Volume 4,257,419